548 related articles for article (PubMed ID: 33493574)
1. Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations.
Garg A; Malviya N; Strunk A; Wright S; Alavi A; Alhusayen R; Alikhan A; Daveluy SD; Delorme I; Goldfarb N; Gulliver W; Hamzavi I; Jaleel T; Kimball AB; Kirby JS; Kirchhof MG; Lester J; Lev-Tov H; Lowes MA; Micheletti R; Orenstein LA; Piguet V; Sayed C; Tan J; Naik HB
J Am Acad Dermatol; 2022 May; 86(5):1092-1101. PubMed ID: 33493574
[TBL] [Abstract][Full Text] [Related]
2. Diseases associated with hidranitis suppurativa: part 2 of a series on hidradenitis.
Scheinfeld N
Dermatol Online J; 2013 Jun; 19(6):18558. PubMed ID: 24011308
[TBL] [Abstract][Full Text] [Related]
3. Recommendations for the management of comorbidity in hidradenitis suppurativa.
Dauden E; Lazaro P; Aguilar MD; Blasco AJ; Suarez C; Marin I; Queiro R; Bassas-Vila J; Martorell A; García-Campayo J
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):129-144. PubMed ID: 28796920
[TBL] [Abstract][Full Text] [Related]
4. Which hidradenitis suppurativa comorbidities should I take into account?
Tzellos T; Zouboulis CC
Exp Dermatol; 2022 Sep; 31 Suppl 1():29-32. PubMed ID: 35737874
[TBL] [Abstract][Full Text] [Related]
5. Spectrum of diseases associated with pyoderma gangrenosum and correlation with effectiveness of therapy: New insights on the diagnosis and therapy of comorbid hidradenitis suppurativa.
Fischer AH; Jourabchi N; Khalifian S; Lazarus GS
Wound Repair Regen; 2022 May; 30(3):338-344. PubMed ID: 35385180
[TBL] [Abstract][Full Text] [Related]
6. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis.
Shlyankevich J; Chen AJ; Kim GE; Kimball AB
J Am Acad Dermatol; 2014 Dec; 71(6):1144-50. PubMed ID: 25440440
[TBL] [Abstract][Full Text] [Related]
7. Autoinflammatory syndromes associated with hidradenitis suppurativa and/or acne.
Vinkel C; Thomsen SF
Int J Dermatol; 2017 Aug; 56(8):811-818. PubMed ID: 28345207
[TBL] [Abstract][Full Text] [Related]
8. The epidemiology of hidradenitis suppurativa.
Ingram JR
Br J Dermatol; 2020 Dec; 183(6):990-998. PubMed ID: 32880911
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population-based study.
Lee JH; Kwon HS; Jung HM; Kim GM; Bae JM
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1784-1790. PubMed ID: 29761904
[TBL] [Abstract][Full Text] [Related]
10. Phenotypes and Pathophysiology of Syndromic Hidradenitis Suppurativa: Different Faces of the Same Disease? A Systematic Review.
Nikolakis G; Kaleta KP; Vaiopoulos AG; Wolter K; Baroud S; Wojas-Pelc A; Zouboulis CC
Dermatology; 2021; 237(5):673-697. PubMed ID: 32942279
[TBL] [Abstract][Full Text] [Related]
11. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa.
Gold DA; Reeder VJ; Mahan MG; Hamzavi IH
J Am Acad Dermatol; 2014 Apr; 70(4):699-703. PubMed ID: 24433875
[TBL] [Abstract][Full Text] [Related]
12. Physical and psychosocial comorbidities of pediatric hidradenitis suppurativa: A retrospective analysis.
Seivright JR; Collier E; Grogan T; Hogeling M; Shi VY; Hsiao JL
Pediatr Dermatol; 2021 Sep; 38(5):1132-1136. PubMed ID: 34463372
[TBL] [Abstract][Full Text] [Related]
13. Concurrent hidradenitis suppurativa, inflammatory acne, dissecting cellulitis of the scalp, and pyoderma gangrenosum in a 16-year-old boy.
Koshelev MV; Garrison PA; Wright TS
Pediatr Dermatol; 2014; 31(1):e20-1. PubMed ID: 24118007
[TBL] [Abstract][Full Text] [Related]
14. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
[TBL] [Abstract][Full Text] [Related]
15. Overall and subgroup prevalence of pyoderma gangrenosum among patients with hidradenitis suppurativa: A population-based analysis in the United States.
Tannenbaum R; Strunk A; Garg A
J Am Acad Dermatol; 2019 Jun; 80(6):1533-1537. PubMed ID: 30738122
[TBL] [Abstract][Full Text] [Related]
16. Pyoderma gangrenosum, acne, suppurative hidradenitis (PASH) and polycystic ovary syndrome: Coincidentally or aetiologically connected?
Zivanovic D; Masirevic I; Ruzicka T; Braun-Falco M; Nikolic M
Australas J Dermatol; 2017 May; 58(2):e54-e59. PubMed ID: 26831949
[TBL] [Abstract][Full Text] [Related]
17. Risk of psoriasis in people with hidradenitis suppurativa: A systematic review and meta-analysis.
Gau SY; Preclaro IAC; Wei JC; Lee CY; Kuan YH; Hsiao YP; Juang SE; Ma KS
Front Immunol; 2022; 13():1033844. PubMed ID: 36532043
[TBL] [Abstract][Full Text] [Related]
18. Prevalence, Risk Factors, and Comorbidities of Hidradenitis Suppurativa.
Miller IM; McAndrew RJ; Hamzavi I
Dermatol Clin; 2016 Jan; 34(1):7-16. PubMed ID: 26617352
[TBL] [Abstract][Full Text] [Related]
19. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life.
Nguyen TV; Damiani G; Orenstein LAV; Hamzavi I; Jemec GB
J Eur Acad Dermatol Venereol; 2021 Jan; 35(1):50-61. PubMed ID: 32460374
[TBL] [Abstract][Full Text] [Related]
20. Endocrinologic Aspects of Hidradenitis Suppurativa.
Karagiannidis I; Nikolakis G; Zouboulis CC
Dermatol Clin; 2016 Jan; 34(1):45-9. PubMed ID: 26617357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
